BioCentury | Oct 21, 2020
Deals

Oct. 21 Quick Takes: Clear path for BMS in MyoKardia deal; plus WuXi Biologics rises, Purdue settles, Actemra, Cara-Vifor and more

Scant competition ahead of BMS-MyoKardia dealAlthough negotiations drove the takeout price for MyoKardia Inc. (NASDAQ:MYOK) up to $225 per share from an initial offer of $185 by Bristol Myers Squibb Co....
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

Rachel Humphrey has joined Black Diamond Therapeutics Inc. (NASDAQ:BDTX) as CMO. Karsten Witt, who has been SVP of clinical development and acting CMO since May 2019, will become SVP of non-clinical development. Previously, Humphrey was...
BioCentury | Aug 8, 2019
Distillery Therapeutics

Glucose-responsive insulin delivery for diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes A UCLA and North Carolina State University team funded by JDRF and Sanofi developed a charge-switchable polymer complex that could help treat diabetes by automatically delivering insulin in response to...
BioCentury | Aug 2, 2019
Translation in Brief

A charged system for insulin delivery

A charge-based glucose-binding switch is the latest technology aimed at enabling automatic insulin control. With proof-of-concept experiments in mice and minipigs, the system could rival preclinical technologies picked up by Eli Lilly, Merck and Novo...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BioCentury | Apr 4, 2019
Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

FDA Commissioner Scott Gottlieb will return to the American Enterprise Institute as a resident fellow after he leaves the agency. His last day at FDA is Friday. Gottlieb expects to work part-time at AEI, where...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
BioCentury | Oct 19, 2018
Company News

Gurnet to acquire Corium as it heads for NDA

Healthcare investor Gurnet Point Capital will acquire drug delivery company Corium International Inc. (NASDAQ:CORI) for $12.50 per share in cash plus $0.50 per share in a contingent value right (CVR). The deal, including the CVR,...
BioCentury | Oct 9, 2018
Politics & Policy

FDA pushes generic competition for transdermal complex drugs

FDA clarified how to develop generic versions of transdermal or topical complex drugs, releasing a series of guidances Tuesday as the agency continues its push for greater generics competition. Complex drugs, especially those with transdermal...
BioCentury | Sep 21, 2018
Company News

Sorrento's Scilex launching ZTlido in October

Scilex Pharmaceuticals Inc. (San Diego, Calif.), a subsidiary of Sorrento Therapeutics Inc. (NASDAQ:SRNE), expects to launch ZTlido 1.8% lidocaine patch in October at a wholesale acquisition cost (WAC) of $8.98 per patch. FDA approved the...
Items per page:
1 - 10 of 1490
BioCentury | Oct 21, 2020
Deals

Oct. 21 Quick Takes: Clear path for BMS in MyoKardia deal; plus WuXi Biologics rises, Purdue settles, Actemra, Cara-Vifor and more

Scant competition ahead of BMS-MyoKardia dealAlthough negotiations drove the takeout price for MyoKardia Inc. (NASDAQ:MYOK) up to $225 per share from an initial offer of $185 by Bristol Myers Squibb Co....
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

Rachel Humphrey has joined Black Diamond Therapeutics Inc. (NASDAQ:BDTX) as CMO. Karsten Witt, who has been SVP of clinical development and acting CMO since May 2019, will become SVP of non-clinical development. Previously, Humphrey was...
BioCentury | Aug 8, 2019
Distillery Therapeutics

Glucose-responsive insulin delivery for diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes A UCLA and North Carolina State University team funded by JDRF and Sanofi developed a charge-switchable polymer complex that could help treat diabetes by automatically delivering insulin in response to...
BioCentury | Aug 2, 2019
Translation in Brief

A charged system for insulin delivery

A charge-based glucose-binding switch is the latest technology aimed at enabling automatic insulin control. With proof-of-concept experiments in mice and minipigs, the system could rival preclinical technologies picked up by Eli Lilly, Merck and Novo...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BioCentury | Apr 4, 2019
Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

FDA Commissioner Scott Gottlieb will return to the American Enterprise Institute as a resident fellow after he leaves the agency. His last day at FDA is Friday. Gottlieb expects to work part-time at AEI, where...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
BioCentury | Oct 19, 2018
Company News

Gurnet to acquire Corium as it heads for NDA

Healthcare investor Gurnet Point Capital will acquire drug delivery company Corium International Inc. (NASDAQ:CORI) for $12.50 per share in cash plus $0.50 per share in a contingent value right (CVR). The deal, including the CVR,...
BioCentury | Oct 9, 2018
Politics & Policy

FDA pushes generic competition for transdermal complex drugs

FDA clarified how to develop generic versions of transdermal or topical complex drugs, releasing a series of guidances Tuesday as the agency continues its push for greater generics competition. Complex drugs, especially those with transdermal...
BioCentury | Sep 21, 2018
Company News

Sorrento's Scilex launching ZTlido in October

Scilex Pharmaceuticals Inc. (San Diego, Calif.), a subsidiary of Sorrento Therapeutics Inc. (NASDAQ:SRNE), expects to launch ZTlido 1.8% lidocaine patch in October at a wholesale acquisition cost (WAC) of $8.98 per patch. FDA approved the...
Items per page:
1 - 10 of 1490